$
₹
$4.831.47% (+0.07)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
1D
1W
1M
1Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
24.08
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-0.13
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Company Profile
Peers
Peers
P/E Ratio
36.23
36.23
1Y Return
35.76%
35.76%
Buy Reco %
79.31
79.31
P/E Ratio
26.65
26.65
1Y Return
54.2%
54.2%
Buy Reco %
45.83
45.83
P/E Ratio
27.88
27.88
1Y Return
32.32%
32.32%
Buy Reco %
88.88
88.88
P/E Ratio
21.55
21.55
1Y Return
33.99%
33.99%
Buy Reco %
15.38
15.38
P/E Ratio
32.18
32.18
1Y Return
47.82%
47.82%
Buy Reco %
57.69
57.69
Peers & Comparison
Peers & Comparison
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. Common Stock | - | 24.08 | - |
| Eli Lilly and Company | 36.23 | 27.10 | 1.27 |
| Johnson & Johnson | 26.65 | 6.78 | 2.97 |
Price Comparison
Price Comparison
1 Month
1 Year
5 Years
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q2 2024
Q2 2025
Q4 2025
Revenue
Net Income
| Financial Year | Q2 2024 | Q2 2025 | Q4 2025 |
|---|---|---|---|
| Total Revenue | 0 | 0 | - |
Gross Profit | - | - | - |
| Net Income | -0.35 | -1.24 | - |
| Net Profit Margin | - | - | - |
